Uploaded image for project: 'eCQM Issue Tracker'
  1. eCQM Issue Tracker
  2. CQM-5715

CMS127v11 clarification on reporting to CMS for MIPS 2022

XMLWordPrintable

    • Icon: EC eCQMs - Eligible Clinicians EC eCQMs - Eligible Clinicians
    • Resolution: Answered
    • Icon: Moderate Moderate
    • None
    • None
    • Mary Kelly
    • 8053249403
    • Cottage Health
    • Hide
      Thank you for you inquiry about CMS127v10. Unspecified formulations of the pneumococcal vaccine may count towards the numerator criteria given they were received during the required timeframe with the appropriate age requirement. For the performance year 2022, implementers may map additional formulations of the pneumococcal conjugate vaccine, including pneumococcal conjugate vaccine 13 valent, pneumococcal conjugate vaccine 15 valent, and pneumococcal conjugate vaccine 20 valent, to the pneumococcal vaccine, unspecified formulation code (CVX code 109) in the Pneumococcal Polysaccharide 23 Vaccine (OID: 2.16.840.1.113883.3.464.1003.110.12.1089) value set.


      ​Unfortunately, the portion of your inquiry specific to CMS suppression of data, is out of scope for the eCQM Issue Tracker. Your question has been redirected to the QualityNet Service Desk where the following ticket is open for you:

      CS1778421
      You will be contacted by their team, and assigned a customer service representative who will work to resolve your inquiry. We are closing this ticket now. Please let us know if you have any additional questions about eCQM logic or specifications.
      Show
      Thank you for you inquiry about CMS127v10. Unspecified formulations of the pneumococcal vaccine may count towards the numerator criteria given they were received during the required timeframe with the appropriate age requirement. For the performance year 2022, implementers may map additional formulations of the pneumococcal conjugate vaccine, including pneumococcal conjugate vaccine 13 valent, pneumococcal conjugate vaccine 15 valent, and pneumococcal conjugate vaccine 20 valent, to the pneumococcal vaccine, unspecified formulation code (CVX code 109) in the Pneumococcal Polysaccharide 23 Vaccine (OID: 2.16.840.1.113883.3.464.1003.110.12.1089) value set. ​Unfortunately, the portion of your inquiry specific to CMS suppression of data, is out of scope for the eCQM Issue Tracker. Your question has been redirected to the QualityNet Service Desk where the following ticket is open for you: CS1778421 You will be contacted by their team, and assigned a customer service representative who will work to resolve your inquiry. We are closing this ticket now. Please let us know if you have any additional questions about eCQM logic or specifications.
    • CMS0127v11
    • CMS127v11 clarification on reporting to CMS for MIPS 2022

      Clarification question - if we submit performance data on this measure for 2022 even though there is a known issue that pneumococcal vaccine does not currently contain the specific codes to capture administration of the pneumococcal conjugate vaccine 15 valent or the pneumococcal conjugate vaccine 20 valent, will we still get performance credit for other vaccine types administered and reported or will CMS suppress that data? Thank you.

            edave Mathematica EC eCQM Team
            m2kelly@sbch.org Mary Kelly (Inactive)
            Votes:
            0 Vote for this issue
            Watchers:
            3 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: